Study Confirms Tesamorelin Significantly Reduces Liver Fat in HIV Patients With NAFLD

— Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced that top-line results, from a study funded by the National Institutes of Health led by Dr. Steve Grinspoon and conducted at the Massachusetts General Hospital and Harvard Medical School and the National Institutes of Health, conclude that tesamorelin significantly reduces liver fat in HIV patients with Non Alcoholic Fatty Liver Disease (NAFLD) which was the primary endpoint of the study. Read More